Management of Lupus Nephritis: An Update.
J Assoc Physicians India
; 70(3): 11-12, 2022 Mar.
Article
em En
| MEDLINE
| ID: mdl-35438287
ABSTRACT
Systemic lupus erythematosus (SLE) is a multisystem autoimmune disease, and lupus nephritis (LN) is associated with increased morbidity and mortality. Renal biopsy is essential and the gold standard to diagnose LN. Extra-glomerular involvement is seen in up to 60% of patients with LN and is associated with poor outcomes. The revised International Society of Nephrology/Renal Pathology Society classification for LN has changed the parameters for activity index scoring, redefined crescent and highlighted the significance of extra-glomerular involvement. Repeat renal biopsy is done for resistant disease or during a flare, usually when atypical features are present or when the baseline biopsy showed non-proliferative histology. Protocol repeat biopsy may prove to be valuable as a monitoring tool in patients with LN. Newer modalities of therapy like multitargeted therapy and biological agents may pave a way for better outcomes with minimal adverse effects to the patients.
Buscar no Google
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Nefrite Lúpica
/
Lúpus Eritematoso Sistêmico
/
Nefrologia
Tipo de estudo:
Diagnostic_studies
/
Guideline
Limite:
Female
/
Humans
/
Male
Idioma:
En
Revista:
J Assoc Physicians India
Ano de publicação:
2022
Tipo de documento:
Article